Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Aquagenic pruritus in essential thrombocythemia is associated with a higher risk of thrombosis.

Le Gall-Ianotto C, Le Calloch R, Couturier MA, Chauveau A, Lippert E, Carré JL, Misery L, Ianotto JC.

J Thromb Haemost. 2019 Jul 25. doi: 10.1111/jth.14588. [Epub ahead of print]

PMID:
31344312
2.

A very potent factor V inhibitor interferes with the levels of all coagulation factors and causes a fatal hemorrhagic syndrome.

Hoffmann C, Amiral J, Rezig S, Kerspern H, Jantzem H, Robin S, Collins A, Mornet C, Mingant F, Pan Petesch B, Ianotto JC, Lippert E, Galinat H.

Eur J Haematol. 2019 Aug;103(2):137-139. doi: 10.1111/ejh.13249. Epub 2019 May 28.

PMID:
31102471
3.

International external quality assurance of JAK2 V617F quantification.

Asp J, Skov V, Bellosillo B, Kristensen T, Lippert E, Dicker F, Schwarz J, Wojtaszewska M, Palmqvist L, Akiki S, Aggerholm A, Tolstrup Andersen M, Girodon F, Kjær L, Oppliger Leibundgut E, Pancrazzi A, Vorland M, Andrikovics H, Kralovics R, Cassinat B, Coucelo M, Eftimov A, Haslam K, Kusec R, Link-Lenczowska D, Lodé L, Matiakowska K, Naguib D, Navaglia F, Novotny GW, Percy MJ, Sudarikov A, Hermouet S, Pallisgaard N.

Ann Hematol. 2019 May;98(5):1111-1118. doi: 10.1007/s00277-018-3570-8. Epub 2018 Dec 8.

4.

MiR-10a and HOXB4 are overexpressed in atypical myeloproliferative neoplasms.

Dumas PY, Mansier O, Prouzet-Mauleon V, Koya J, Villacreces A, Brunet de la Grange P, Luque Paz D, Bidet A, Pasquet JM, Praloran V, Salin F, Kurokawa M, Mahon FX, Cardinaud B, Lippert E.

BMC Cancer. 2018 Nov 12;18(1):1098. doi: 10.1186/s12885-018-4993-2.

5.

Statin exposure and thrombosis risk in patients with myeloproliferative neoplasms.

Delluc A, Lacut K, Pan-Petesch B, Galinat H, Lippert E, Ianotto JC.

Thromb Res. 2018 Jul;167:57-59. doi: 10.1016/j.thromres.2018.05.014. Epub 2018 May 16. No abstract available.

PMID:
29787944
6.

Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase.

Mollard LM, Chauveau A, Boyer-Perrard F, Douet-Guilbert N, Houot R, Quintin-Roué I, Couturier MA, Dagorne A, Malou M, Le Calloch R, Luycx O, Thepot S, Hunault M, Guillerm G, Berthou C, Ugo V, Lippert É, Ianotto JC.

Leuk Lymphoma. 2018 Dec;59(12):2812-2820. doi: 10.1080/10428194.2018.1441408. Epub 2018 Apr 4.

PMID:
29616837
7.

Comparison of four methods to assess high-on platelet reactivity under P2Y12 receptor inhibitor.

Mingant F, Didier R, Gilard M, Martin F, Nicol PP, Ugo V, Lippert E, Galinat H.

Platelets. 2018 May;29(3):257-264. doi: 10.1080/09537104.2018.1453058. Epub 2018 Mar 26.

PMID:
29580115
8.

Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study.

Mansier O, Luque Paz D, Ianotto JC, Le Bris Y, Chauveau A, Boyer F, Conejero C, Fitoussi O, Riou J, Adiko D, Touati M, Chauzeix J, Viallard JF, Béné MC, Giraudier S, Ugo V, Lippert E.

Am J Hematol. 2018 Aug;93(4):E84-E86. doi: 10.1002/ajh.25014. Epub 2018 Jan 12. No abstract available.

9.

Non-adherence to treatment with cytoreductive and/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study).

Le Calloch R, Lacut K, Le Gall-Ianotto C, Nowak E, Abiven M, Tempescul A, Dalbies F, Eveillard JR, Ugo V, Giraudier S, Guillerm G, Lippert E, Berthou C, Ianotto JC.

Haematologica. 2018 Apr;103(4):607-613. doi: 10.3324/haematol.2017.180448. Epub 2017 Dec 15.

10.

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Ianotto JC, Chauveau A, Boyer-Perrard F, Gyan E, Laribi K, Cony-Makhoul P, Demory JL, de Renzis B, Dosquet C, Rey J, Roy L, Dupriez B, Knoops L, Legros L, Malou M, Hutin P, Ranta D, Benbrahim O, Ugo V, Lippert E, Kiladjian JJ.

Haematologica. 2018 Mar;103(3):438-446. doi: 10.3324/haematol.2017.181297. Epub 2017 Dec 7.

11.

Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.

Mahé K, Delluc A, Chauveau A, Castellant P, Mottier D, Dalbies F, Berthou C, Guillerm G, Lippert E, Ianotto JC.

Ann Hematol. 2018 Jan;97(1):101-107. doi: 10.1007/s00277-017-3164-x. Epub 2017 Nov 21.

PMID:
29164292
12.

Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.

Perrier-Cornet A, Ianotto JC, Mingant F, Perrot M, Lippert E, Galinat H.

Platelets. 2018 Nov;29(7):723-728. doi: 10.1080/09537104.2017.1361018. Epub 2017 Nov 1.

PMID:
29090588
13.

The MLL recombinome of acute leukemias in 2017.

Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, Sutton R, Venn NC, Emerenciano M, Pombo-de-Oliveira MS, Barbieri Blunck C, Almeida Lopes B, Zuna J, Trka J, Ballerini P, Lapillonne H, De Braekeleer M, Cazzaniga G, Corral Abascal L, van der Velden VHJ, Delabesse E, Park TS, Oh SH, Silva MLM, Lund-Aho T, Juvonen V, Moore AS, Heidenreich O, Vormoor J, Zerkalenkova E, Olshanskaya Y, Bueno C, Menendez P, Teigler-Schlegel A, Zur Stadt U, Lentes J, Göhring G, Kustanovich A, Aleinikova O, Schäfer BW, Kubetzko S, Madsen HO, Gruhn B, Duarte X, Gameiro P, Lippert E, Bidet A, Cayuela JM, Clappier E, Alonso CN, Zwaan CM, van den Heuvel-Eibrink MM, Izraeli S, Trakhtenbrot L, Archer P, Hancock J, Möricke A, Alten J, Schrappe M, Stanulla M, Strehl S, Attarbaschi A, Dworzak M, Haas OA, Panzer-Grümayer R, Sedék L, Szczepański T, Caye A, Suarez L, Cavé H, Marschalek R.

Leukemia. 2018 Feb;32(2):273-284. doi: 10.1038/leu.2017.213. Epub 2017 Jul 13.

14.

Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.

Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G, Lippert E, Delluc A.

Int J Hematol. 2017 Oct;106(4):517-521. doi: 10.1007/s12185-017-2282-5. Epub 2017 Jun 16.

PMID:
28623609
15.

Anthocyanins Prevent Colorectal Cancer Development in a Mouse Model.

Lippert E, Ruemmele P, Obermeier F, Goelder S, Kunst C, Rogler G, Dunger N, Messmann H, Hartmann A, Endlicher E.

Digestion. 2017;95(4):275-280. doi: 10.1159/000475524. Epub 2017 May 12.

16.

Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation.

Bidet A, Chollet C, Gardembas M, Nicolini FE, Genet P, Delmer A, Caillot D, Dulucq S, Mahon FX, Lippert E.

Br J Haematol. 2018 Jul;182(1):148-152. doi: 10.1111/bjh.14748. Epub 2017 May 9. No abstract available.

PMID:
28485070
17.

The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes.

Le Clech L, Sakka M, Meskar A, Kerspern H, Eveillard JR, Berthou C, Buors C, Lippert E, Guillerm G, Quintin-Roué I, Carré JL, Ianotto JC.

Leuk Lymphoma. 2017 Nov;58(11):2582-2587. doi: 10.1080/10428194.2017.1312380. Epub 2017 May 9.

PMID:
28482711
18.

MYB-GATA1 fusion promotes basophilic leukaemia: involvement of interleukin-33 and nerve growth factor receptors.

Ducassou S, Prouzet-Mauléon V, Deau MC, Brunet de la Grange P, Cardinaud B, Soueidan H, Quelen C, Brousset P, Pasquet JM, Moreau-Gaudry F, Arock M, Mahon FX, Lippert E.

J Pathol. 2017 Jul;242(3):347-357. doi: 10.1002/path.4908. Epub 2017 May 29.

PMID:
28418072
19.

Sequential analysis of 18 genes in polycythemia vera and essential thrombocythemia reveals an association between mutational status and clinical outcome.

Luque Paz D, Chauveau A, Boyer F, Buors C, Samaison L, Cottin L, Seegers V, Férec C, Le Maréchal C, Gueguen P, Lippert E, Ianotto JC, Ugo V.

Genes Chromosomes Cancer. 2017 May;56(5):354-362. doi: 10.1002/gcc.22437. Epub 2017 Feb 1.

PMID:
27997717
20.

JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

Ianotto JC, Chauveau A, Mottier D, Ugo V, Berthou C, Lippert E, Delluc A.

Ann Hematol. 2017 Mar;96(3):383-386. doi: 10.1007/s00277-016-2853-1. Epub 2016 Oct 20.

PMID:
27766390
21.

Absence of CALR mutations in JAK2-negative polycythemia.

Chauveau A, Nibourel O, Tondeur S, Paz DL, Mansier O, Paul F, Wemeau M, Preudhomme C, Lippert E, Ugo V; French Intergroup of Myeloproliferative Neoplasms.

Haematologica. 2017 Jan;102(1):e15-e16. doi: 10.3324/haematol.2016.154799. Epub 2016 Oct 6. No abstract available.

22.

Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Bilhou-Nabéra C, Bidet A, Eclache V, Lippert E, Mozziconacci MJ.

Ann Biol Clin (Paris). 2016 Oct 1;74(5):517-523. Review.

PMID:
27477946
23.

High-pulse-energy mid-infrared fractional-image-rotation-enhancement ZnGeP<sub>2</sub> optical parametric oscillator.

Eichhorn M, Schellhorn M, Haakestad MW, Fonnum H, Lippert E.

Opt Lett. 2016 Jun 1;41(11):2596-9. doi: 10.1364/OL.41.002596.

PMID:
27244423
24.

Multiple Electrode Aggregometry is an adequate method for aspirin response testing in myeloproliferative neoplasms and differentiates the mechanisms of aspirin resistance.

Gillet B, Ianotto JC, Mingant F, Didier R, Gilard M, Ugo V, Lippert E, Galinat H.

Thromb Res. 2016 Jun;142:26-32. doi: 10.1016/j.thromres.2016.04.006. Epub 2016 Apr 14.

PMID:
27105311
25.

Genetic differences between paediatric and adult Burkitt lymphomas.

Havelange V, Pepermans X, Ameye G, Théate I, Callet-Bauchu E, Barin C, Penther D, Lippert E, Michaux L, Mugneret F, Dastugue N, Raphaël M, Vikkula M, Poirel HA.

Br J Haematol. 2016 Apr;173(1):137-44. doi: 10.1111/bjh.13925. Epub 2016 Feb 16.

PMID:
26887776
26.

The peculiar 11q-gain/loss aberration reported in a subset of MYC-negative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma.

Havelange V, Ameye G, Théate I, Callet-Bauchu E, Lippert E, Luquet I, Raphaël M, Vikkula M, Poirel HA.

Cancer Genet. 2016 Mar;209(3):117-8. doi: 10.1016/j.cancergen.2015.12.005. Epub 2015 Dec 15. No abstract available.

PMID:
26776268
27.

Analysis of RUNX1 rearrangements: insights into leukaemogenesis mechanisms.

Bidet A, Laharanne E, Achard S, Migeon M, Moreau C, Lippert E.

Br J Haematol. 2016 Nov;175(4):738-740. doi: 10.1111/bjh.13881. Epub 2016 Jan 13. No abstract available.

PMID:
26765924
28.

JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens.

Mansier O, Migeon M, Etienne G, Bidet A, Lippert E.

Leuk Lymphoma. 2016 Aug;57(8):1949-51. doi: 10.3109/10428194.2015.1116122. Epub 2016 Jan 4. No abstract available.

PMID:
26727159
29.

STAT1 activation in association with JAK2 exon 12 mutations.

Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR.

Haematologica. 2016 Jan;101(1):e15-9. doi: 10.3324/haematol.2015.128546. Epub 2015 Dec 3. No abstract available.

30.

Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 (V617F) and JAK2 exon 12 allele burden disappearance during the follow-up of two patients.

Mahé K, Luque Paz D, Couturier MA, Chauveau A, Quintin-Roué I, Berthou C, Ugo V, Lippert E, Ianotto JC.

Ann Hematol. 2016 Feb;95(3):529-31. doi: 10.1007/s00277-015-2559-9. Epub 2015 Nov 27. No abstract available.

PMID:
26611851
31.

Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.

Mansier O, Migeon M, Saint-Lézer A, James C, Verger E, Robin M, Socié G, Bidet A, Mahon FX, Cassinat B, Lippert E.

J Mol Diagn. 2016 Jan;18(1):68-74. doi: 10.1016/j.jmoldx.2015.07.007. Epub 2015 Nov 18.

PMID:
26596525
32.

Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.

Luque Paz D, Ianotto JC, Chauveau A, Guibourg B, Lecucq L, Lippert E, Ugo V.

Ann Hematol. 2016 Jan;95(2):349-50. doi: 10.1007/s00277-015-2518-5. Epub 2015 Oct 13. No abstract available.

PMID:
26459144
33.

Galectin-3 Modulates Experimental Colitis.

Lippert E, Stieber-Gunckel M, Dunger N, Falk W, Obermeier F, Kunst C.

Digestion. 2015;92(1):45-53. doi: 10.1159/000431312. Epub 2015 Jul 17.

PMID:
26202676
34.

CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia.

Gioia R, Trégoat C, Dumas PY, Lagarde V, Prouzet-Mauléon V, Desplat V, Sirvent A, Praloran V, Lippert E, Villacreces A, Leconet W, Robert B, Vigon I, Roche S, Mahon FX, Pasquet JM.

J Pathol. 2015 Sep;237(1):14-24. doi: 10.1002/path.4561. Epub 2015 Jun 4.

PMID:
25965880
35.

Molecular diagnostics of myeloproliferative neoplasms.

Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet.

Eur J Haematol. 2015 Oct;95(4):270-9. doi: 10.1111/ejh.12578. Epub 2015 May 18. Review.

PMID:
25951317
36.

Novel fusion between the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with chronic myeloid leukemia-like neoplasm: undetectable residual disease after imatinib therapy.

Cluzeau T, Lippert E, Cayuela JM, Maarek O, Migeon M, Noguera ME, Dombret H, Rea D.

Eur J Haematol. 2015 Nov;95(5):480-3. doi: 10.1111/ejh.12576. Epub 2015 May 20.

PMID:
25941032
37.

Gastrointestinal endoscopy in patients aged 75 years and older: risks, complications, and findings--a retrospective study.

Lippert E, Herfarth HH, Grunert N, Endlicher E, Klebl F.

Int J Colorectal Dis. 2015 Mar;30(3):363-6. doi: 10.1007/s00384-014-2088-3. Epub 2014 Dec 12.

PMID:
25503802
38.

A novel cryptic insertion of CBFB into MYH11: importance of FISH probe design.

Bidet A, Laharanne E, Struski S, Luquet I, Lippert E.

Cancer Genet. 2014 Oct-Dec;207(10-12):516-7. doi: 10.1016/j.cancergen.2014.09.050. Epub 2014 Oct 5. No abstract available.

PMID:
25458460
39.

ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?

Etienne G, Dulucq S, Lascaux A, Schmitt A, Bidet A, Fort MP, Lippert E, Bureau C, Adiko D, Hayette S, Reiffers J, Nicolini FE, Mahon FX.

Am J Hematol. 2015 Jan;90(1):37-41. doi: 10.1002/ajh.23864. Epub 2014 Oct 25.

40.

Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.

Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, Girodon F, Alexandre JH, Mansier O, Viallard JF, Lippert E, Murati A, Mozziconacci MJ, Saussoy P, Vekemans MC, Knoops L, Pasquier F, Ribrag V, Solary E, Plo I, Constantinescu SN, Casadevall N, Vainchenker W, Marzac C, Bluteau O.

Leukemia. 2015 Jan;29(1):249-52. doi: 10.1038/leu.2014.270. Epub 2014 Sep 12. No abstract available.

PMID:
25212275
41.

Golimumab in unresponsive ulcerative colitis.

Lippert E, Müller M, Ott C.

Biologics. 2014 May 27;8:207-10. doi: 10.2147/BTT.S39161. eCollection 2014. Review.

42.

Clinical and biological characterization of patients with low (0.1-2%) JAK2V617F allele burden at diagnosis.

Lippert E, Mansier O, Migeon M, Denys B, Nilsson A, Rosmond C, Lodé L, Ugo V, Lascaux A, Bellosillo B, Martinez-Lopez J, Naguib D, Gachard N, Maroc N, Hermouet S.

Haematologica. 2014 Jul;99(7):e98-101. doi: 10.3324/haematol.2014.107656. Epub 2014 May 16. No abstract available.

43.

14q deletions are associated with trisomy 12, NOTCH1 mutations and unmutated IGHV genes in chronic lymphocytic leukemia and small lymphocytic lymphoma.

Cosson A, Chapiro E, Belhouachi N, Cung HA, Keren B, Damm F, Algrin C, Lefebvre C, Fert-Ferrer S, Luquet I, Gachard N, Mugneret F, Terre C, Collonge-Rame MA, Michaux L, Rafdord-Weiss I, Talmant P, Veronese L, Nadal N, Struski S, Barin C, Helias C, Lafage M, Lippert E, Auger N, Eclache V, Roos-Weil D, Leblond V, Settegrana C, Maloum K, Davi F, Merle-Beral H, Lesty C, Nguyen-Khac F; Groupe Francophone de Cytogénétique Hématologique.

Genes Chromosomes Cancer. 2014 Aug;53(8):657-66. doi: 10.1002/gcc.22176. Epub 2014 Apr 12.

PMID:
24729385
44.

Mid-infrared source with 0.2 J pulse energy based on nonlinear conversion of Q-switched pulses in ZnGeP2.

Haakestad MW, Fonnum H, Lippert E.

Opt Express. 2014 Apr 7;22(7):8556-64. doi: 10.1364/OE.22.008556.

PMID:
24718227
45.

Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis.

Broséus J, Lippert E, Harutyunyan AS, Jeromin S, Zipperer E, Florensa L, Milosevic JD, Haferlach T, Germing U, Luño E, Schnittger S, Kralovics R, Girodon F.

Leukemia. 2014 Jun;28(6):1374-6. doi: 10.1038/leu.2014.49. Epub 2014 Jan 30. No abstract available.

PMID:
24476766
46.

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.

Etienne G, Dulucq S, Nicolini FE, Morisset S, Fort MP, Schmitt A, Etienne M, Hayette S, Lippert E, Bureau C, Tigaud I, Adiko D, Marit G, Reiffers J, Mahon FX.

Haematologica. 2014 Mar;99(3):458-64. doi: 10.3324/haematol.2013.095158. Epub 2013 Dec 20.

47.

Physiologic TLR9-CpG-DNA interaction is essential for the homeostasis of the intestinal immune system.

Hofmann C, Dunger N, Doser K, Lippert E, Siller S, Edinger M, Falk W, Obermeier F.

Inflamm Bowel Dis. 2014 Jan;20(1):136-43. doi: 10.1097/01.MIB.0000436276.19755.c1.

PMID:
24247649
48.

Identification of methylguanine methyltransferase polymorphisms as genetic markers of individual susceptibility to therapy-related myeloid neoplasms.

Dubois J, Etienne G, Laroche-Clary A, Lascaux A, Bidet A, Lippert E, Ait-ouferoukh S, Saada V, Micol JB, Bouabdallah K, Robert J.

Eur J Cancer. 2014 Jan;50(2):418-24. doi: 10.1016/j.ejca.2013.10.012. Epub 2013 Nov 14.

PMID:
24238921
49.

Variable behavior of iPSCs derived from CML patients for response to TKI and hematopoietic differentiation.

Bedel A, Pasquet JM, Lippert E, Taillepierre M, Lagarde V, Dabernat S, Dubus P, Charaf L, Beliveau F, de Verneuil H, Richard E, Mahon FX, Moreau-Gaudry F.

PLoS One. 2013 Aug 23;8(8):e71596. doi: 10.1371/journal.pone.0071596. eCollection 2013.

50.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study.

Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D.

Leukemia. 2013 Oct;27(10):2032-9. doi: 10.1038/leu.2013.219. Epub 2013 Jul 17.

Supplemental Content

Loading ...
Support Center